Reshma Kewalramani sold $7.8M of VRTX
CEO & President at VERTEX PHARMACEUTICALS INC / MA. 15,198 shares at an average of $515.00, traded Nov 8, 2024, filed Nov 12, 2024.
Score components
- +25RoleCEO
- +25Trade size$7.8M at market
- +5Share of holdings soldSold 17% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -5.3%, 3m -7.1%, 6m -11.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-24-000225, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 8, 2024 | SOpen-market sale Common Stock10b5-1 | -15,198 | $515.00 | $7.8M | 75,772 | Nov 12, 2024 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -7% | |
| 35Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Joy Liu EVP and Chief Legal Officer | $442k 892 shares | -4% | |
| 35Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 55Moderate | VERTEX PHARMACEUTICALS INC / MA | Reshma Kewalramani CEO & President | $20M 40,000 shares | -29% | |
| 21Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $173k 357 shares | -5% | |
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $108k 223 shares | -3% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $325k 668 shares | -3% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Jonathan Biller EVP and Chief Legal Officer | $460k 945 shares | -6% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Mark E. Bunnage EVP, Chief Scientific Officer | $302k 620 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.